How GLP-1 Drugs Ozempic and Wegovy Work to Regulate Glucose and Appetite

Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed from niche diabetes treatments into a global pharmacological phenomenon.

By mimicking a natural gut hormone, these medications regulate blood glucose and appetite, with recent clinical evidence suggesting systemic benefits for cardiovascular, respiratory, and neurological health, despite ongoing questions regarding long-term safety and regulation.

As WBUR reported in a July 2026 rebroadcast, this widespread utilization has moved well beyond the original clinical intent of managing type 2 diabetes, prompting researchers to scrutinize the systemic mechanism of action—the specific biological process by which a drug produces its effect—that allows these compounds to influence diverse physiological systems.

  • GLP-1 agonists mimic a natural gut hormone that signals the pancreas to increase insulin secretion only when blood glucose levels are elevated.
  • These drugs suppress glucagon, a hormone that typically triggers the liver to release stored glucose into the bloodstream, thereby preventing post-meal spikes.
  • Beyond glucose control, these receptors located in the brainstem influence satiety, effectively slowing gastric emptying and modulating hunger signals.

The science underpinning current blockbusters like Ozempic and Wegovy dates back to foundational work in the 1970s and 1980s. Dr. Jens Juul Holst, a professor at the University of Copenhagen, shifted his focus from surgical training to endocrinology after observing unexpected hypoglycemia—abnormally low blood glucose—in post-operative patients.

His team sought to isolate the incretin effect, the process by which gut hormones amplify insulin secretion following the ingestion of nutrients.

In 1993, clinical investigations confirmed that infusions of these peptides could normalize blood glucose in diabetic patients within four hours. The discovery relied on understanding the proglucagon gene, which encodes not only glucagon but also GLP-1 and GLP-2. This molecular distinction allowed researchers to synthesize the specific GLP-1 sequences that now serve as the backbone for modern metabolic therapy.

The pharmaceutical industry has shifted dramatically as these drugs gained broad clinical traction. By 2024, the market capitalization of Novo Nordisk, the manufacturer of Ozempic and Wegovy, surpassed the entire GDP of its home country, Denmark.

Questions have been raised regarding whether GLP-1 drugs should be more aggressively regulated in the United States.

Metric Clinical Context
Mechanism GLP-1 Receptor Agonism
Primary Action Insulinotropic (stimulates insulin)
Secondary Action Glucagon suppression & satiety
Common Indications Type 2 Diabetes, Obesity
Emerging Research Cardiovascular, Renal, & Neuro-protection

Patients with a history of pancreatitis or severe gastrointestinal disease require careful medical supervision.

Individuals experiencing persistent vomiting, severe abdominal pain, or signs of gallbladder disease should seek immediate medical consultation. Because these medications alter gastric motility, they may interfere with the absorption of other oral medications.

Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Detroit Mercy Track Schedule Announced for 2026-27 Season

Convicted Attorney Andy Allman Files Prison Lawsuits Against Victims